FDA Updates Risks in Capecitabine, Fluorouracil Labels

by | Feb 6, 2026 | Health

Spread the love
The labeling updates address the risk of early-onset toxicity, including life-threatening adverse events in patients with DPD deficiency who are treated with the drugs.
Medscape Medical News

Written By

Written by Albert Pham, News Curator and Blogger

Related Posts

0 Comments